KV7 potassium channels

KV7 potassium channels: a new therapeutic target in smooth muscle disorders

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

KV7 potassium channels : a new therapeutic target in smooth muscle disorders. / Stott, Jennifer B; Jepps, Thomas Andrew; Greenwood, Iain A.

In: Drug Discovery Today, Vol. 19, No. 4, 12.12.2014, p. 413-424.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stott, JB, Jepps, TA & Greenwood, IA 2014, 'KV7 potassium channels: a new therapeutic target in smooth muscle disorders', Drug Discovery Today, vol. 19, no. 4, pp. 413-424. https://doi.org/10.1016/j.drudis.2013.12.003

APA

Stott, J. B., Jepps, T. A., & Greenwood, I. A. (2014). KV7 potassium channels: a new therapeutic target in smooth muscle disorders. Drug Discovery Today, 19(4), 413-424. https://doi.org/10.1016/j.drudis.2013.12.003

Vancouver

Stott JB, Jepps TA, Greenwood IA. KV7 potassium channels: a new therapeutic target in smooth muscle disorders. Drug Discovery Today. 2014 Dec 12;19(4):413-424. https://doi.org/10.1016/j.drudis.2013.12.003

Author

Stott, Jennifer B ; Jepps, Thomas Andrew ; Greenwood, Iain A. / KV7 potassium channels : a new therapeutic target in smooth muscle disorders. In: Drug Discovery Today. 2014 ; Vol. 19, No. 4. pp. 413-424.

Bibtex

@article{845bc0e99c1646d0a6e7bcceca7e7be3,

title = "KV7 potassium channels: a new therapeutic target in smooth muscle disorders",

abstract = "Potassium channels are key regulators of smooth muscle tone, with increases in activity resulting in hyperpolarisation of the cell membrane, which acts to oppose vasoconstriction. Several potassium channels exist within smooth muscle, but the KV7 family of voltage-gated potassium channels have been identified as being crucial mediators of this process in a variety of smooth muscle. Recently, KV7 channels have been shown to be involved in the pathogenesis of hypertension, as well as being implicated in other smooth muscle disorders, providing a new and inviting target for smooth muscle disorders.",

author = "Stott, {Jennifer B} and Jepps, {Thomas Andrew} and Greenwood, {Iain A}",

note = "Copyright {\textcopyright} 2013. Published by Elsevier Ltd.",

year = "2014",

month = dec,

day = "12",

doi = "10.1016/j.drudis.2013.12.003",

language = "English",

volume = "19",

pages = "413--424",

journal = "Drug Discovery Today: BIOSILICO",

issn = "1359-6446",

publisher = "Elsevier Ltd. * Trends Journals",

number = "4",

}

RIS

TY - JOUR

T1 - KV7 potassium channels

T2 - a new therapeutic target in smooth muscle disorders

AU - Stott, Jennifer B

AU - Jepps, Thomas Andrew

AU - Greenwood, Iain A

PY - 2014/12/12

Y1 - 2014/12/12

N2 - Potassium channels are key regulators of smooth muscle tone, with increases in activity resulting in hyperpolarisation of the cell membrane, which acts to oppose vasoconstriction. Several potassium channels exist within smooth muscle, but the KV7 family of voltage-gated potassium channels have been identified as being crucial mediators of this process in a variety of smooth muscle. Recently, KV7 channels have been shown to be involved in the pathogenesis of hypertension, as well as being implicated in other smooth muscle disorders, providing a new and inviting target for smooth muscle disorders.

AB - Potassium channels are key regulators of smooth muscle tone, with increases in activity resulting in hyperpolarisation of the cell membrane, which acts to oppose vasoconstriction. Several potassium channels exist within smooth muscle, but the KV7 family of voltage-gated potassium channels have been identified as being crucial mediators of this process in a variety of smooth muscle. Recently, KV7 channels have been shown to be involved in the pathogenesis of hypertension, as well as being implicated in other smooth muscle disorders, providing a new and inviting target for smooth muscle disorders.

U2 - 10.1016/j.drudis.2013.12.003

DO - 10.1016/j.drudis.2013.12.003

M3 - Journal article

C2 - 24333708

VL - 19

SP - 413

EP - 424

JO - Drug Discovery Today: BIOSILICO

JF - Drug Discovery Today: BIOSILICO

SN - 1359-6446

IS - 4

ER -

ID: 108539203